Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.

ABSTRACT: BACKGROUND:Tumour budding is an important prognostic factor in colorectal cancer (CRC). Molecular profiling of tumour buds suggests (partial) epithelial-mesenchymal transition and cancer stem-cell phenotype, similarly described in the "mesenchymal" Consensus Molecular Subtype 4 (CMS4), which identifies a particularly poor prognostic subgroup. Here, we determine the association of tumour budding with CMS classification, prognosis, and response to therapy. METHODS:AMC-AJCCII-90 cohort (n?=?76, stage II) was evaluated for peritumoural budding on H&E slides. LUMC (n?=?270, stage I-IV), CAIRO (n?=?504, metastatic CRC) and CAIRO2 (n?=?472, metastatic CRC) cohorts were investigated for intratumoural budding using pan-cytokeratin-stained tissue microarrays. Budding was scored as count/area, then classified as <5 or ?5 buds. For all cohorts, CMS classifications were available (gene-expression/immunohistochemistry-based classifiers). RESULTS:High (?5) budding predicted a worse outcome in multivariate analysis in AMC-AJCCII-90 (p?=?0.018), LUMC (p?

SUBMITTER: Trinh A 

PROVIDER: S-EPMC6251036 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature